Product Description
CodonRX | AI is formulated with a scientifically advanced strain of Lactobacillus acidophilus, named NCK2025. NCK2025 was selected and designed for gut health by reducing inflammatory fatty acids (known as lipoteichoic acid) on the probiotic bacteria’s surface [1,2,3,4]. This product is unique on the market and patent protected worldwide (e.g. USPTO #9,340,792 and #9,980,992). Lactobacillus acidophilus is the most comprehensively studied probiotic and has been proven to form a symbiotic relationship with the human gastrointestinal tract. Lactobacillus acidophilus helps to improve the balance between the beneficial and harmful bacteria that live in the human gut. Lactobacillus acidophilus NCK2025, the active ingredient in CodonRX | AI, improves upon generic Lactobacillus acidophilus with its patented approach. References: [1] Mohamadzadeh M, Pfeiler EA, Brown JB, et al. Regulation of induced colonic inflammation by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc Natl Acad Sci U S A. 2011;108 Suppl 1(Suppl 1):4623-4630. doi:10.1073/pnas.1005066107 [2] Zadeh M, Khan MW, Goh YJ, et al. Induction of intestinal pro-inflammatory immune responses by lipoteichoic acid. J Inflamm (Lond). 2012;9:7. Published 2012 Mar 16. doi:10.1186/1476-9255-9-7 [3] Khazaie, K., Zadeh, M., Khan, M. W., Bere, P., Gounari, F., Dennis, K., Blatner, N. R., Owen, J. L., Klaenhammer, T. R., & Mohamadzadeh, M. (2012). Abating colon cancer polyposis by Lactobacillus acidophilus deficient in lipoteichoic acid. Proceedings of the National Academy of Sciences of the United States of America, 109(26), 10462–10467. https://doi.org/10.1073/pnas.1207230109 [4] Khan, M. W., Zadeh, M., Bere, P., Gounaris, E., Owen, J., Klaenhammer, T., & Mohamadzadeh, M. (2012). Modulating intestinal immune responses by lipoteichoic acid-deficient Lactobacillus acidophilus. Immunotherapy, 4(2), 151–161. https://doi.org/10.2217/imt.11.163